Nephritic, hepatic and immune failures would lead to the overload of endogenous toxic molecules (e.g. bilirubin, cholic acid, uric acid, creatinine etc.) in human bodies. It is fatal in most cases and extracorporeal blood purification (ECBP) is powerful first-aid therapy. Adsorbents are key parts of ECBP apparatus. Mesoporous silicas should be promising candidates for these medical adsorbents, but there is no report about this. Herein, pure and amine-grafted mesoporous silicas have been applied to adsorb bilirubin, cholic acid, uric acid, creatinine and phenobarbital for the first time. These mesoporous materials show high adsorption capacities for bilirubin and uric acid in phosphate buffer solution (PBS). Effects of pore sizes, amine-modification, temperature and ionic strength on their bilirubin adsorption capacities have been studied in detail.
hemodialysis, hemofiltration, hemoperfusion and plasma exchange, is powerful first-aid therapy to remove toxins from human hematic system [2] . Adsorbents are the most important parts of ECBP apparatus. Active carbon, chitosan and resins have been applied in ECBP [3] [4] [5] [6] . However, development of medical adsorbents with high adsorption capacity and excellent blood compatibility is still a great challenge. Mesoporous silicas, which have high surface area, uniform pore size and abundant Si-OH groups, have been used as adsorbents for heavy metal ions [7] [8] [9] [10] and organic pollutants [10] and toxic gas [10] , etc. Recently, they have also been applied to medicine storage and targeting therapy [7, 11, 12] . Mesoporous silicas should also be promising candidates for medical adsorbents of ECBP to remove the above-mentioned toxins from human hematic system. However, there are few reports about this.
Herein this article, pure and amine-grafted mesoporous silicas have been prepared and applied to adsorb bilirubin, cholic acid, uric acid, creatinine, etc. Effects of pore size, amine-grafting, temperature and ionic strength on the bilirubin adsorption capacities of these materials have been studied in detail.
EXPERIMENTAL

A. Materials. Bilirubin (~99%) was supplied from Alfa
Aesar Chemical Company. The molecular structure of bilirubin has been shown in Fig. 1 [13] . In a typical synthesis, 4 g of block copolymer surfactant EO20PO70EO20 (Pluronic P123, BASF) was dissolved in 30 g of distilled water and 120 ml of 2 M HCl with stirring, followed by addition of 8.5 g of TEOS at 35-40℃. This gel was continuously stirred for 24 h and then crystallized in a glass bottle at 100 ℃ for 48 h. After crystallization, the solid product was filtered, washed with distilled water, and dried in air at 100℃. The material was calcined in air at 530℃ for 6 h to remove the surfactant template and obtain a white parent powder (SBA-15). For preparation of larger pore SBA-15, 2 g of P123 was dissolved in 75 ml 1 M HCl with stirring, followed by addition of 1.38 ml C. Preparation of mesoporous silica KIT-6. The mesoporous silica with cubic Ia3d symmetry (designated as KIT-6) was prepared according to the published procedure using tri-block copolymer Pluronic P123 as template by adding of n-butanol in an acidic aqueous solution [16] . Typically, 6 g of surfactant P123 and 6 g of n-butanol were dissolved in the solution of 217 g of distilled water and 11.4 g of concentrated HCl (37 wt%). To this homogeneous solution, 12.9 g of TEOS was added under stirring at 37℃ and continuously stirred for 24 h. After that, the mixture was transferred to Teflon-lined autoclaves and heated at 100℃ for 24 h. The solid product was filtered, washed with distilled water and calcined at 550℃ for 5 h to get KIT-6. For SBA-15 and FSBA-15, as shown in Table 1 , the surface areas, pore diameters and volumes all decrease after the introduction of amine groups (2N-SBA-15 and 2N-FSBA-15).
D. Preparation of mesoporous silica
However, all amine-grafted mesoporous silicas show higher adsorption capacities than their pure parent mesoporous silicas.
The same results can also be obtained from C. Effect of initial concentrations of bilirubin. Figure 3 shows 
